語系:
繁體中文
English
說明(常見問題)
登入
回首頁
切換:
標籤
|
MARC模式
|
ISBD
Immunotherapy
~
SpringerLink (Online service)
Immunotherapy
紀錄類型:
書目-語言資料,印刷品 : Monograph/item
正題名/作者:
Immunotherapy/ edited by Aung Naing, Joud Hajjar.
其他作者:
Hajjar, Joud.
面頁冊數:
XII, 339 p. 44 illus., 35 illus. in color.online resource. :
Contained By:
Springer Nature eBook
標題:
Oncology. -
電子資源:
https://doi.org/10.1007/978-3-030-41008-7
ISBN:
9783030410087
Immunotherapy
Immunotherapy
[electronic resource] /edited by Aung Naing, Joud Hajjar. - 3rd ed. 2020. - XII, 339 p. 44 illus., 35 illus. in color.online resource. - Advances in Experimental Medicine and Biology,12440065-2598 ;. - Advances in Experimental Medicine and Biology,889.
Overview of Basic Immunology and Clinical Application -- Advances in Diagnostic Procedures and their Applications in the era of Cancer Immunotherapy -- Immunotherapy for Melanoma -- Immunotherapy in Lung Cancer: From a minor God to the Olympus -- Immunotherapy in Gastrointestinal Malignancies -- Current Landscape of Immunotherapy in Genitourinary Malignancies -- Immuno-oncology for Gynecologic Malignancies -- Immunotherapy for Neuro-Oncology -- Immunotherapy and Radiation -- CAR T-cells -- Skin Reactions to Immune Checkpoint Inhibitors -- Gastrointestinal Tract Adverse Events -- Immune-Related Adverse Events: Pneumonitis -- Hepatobiliary Adverse Events -- Immune Checkpoint Inhibitors (ICIs) Related Cardiotoxicity -- Renal Toxicity -- Immune-Related Oral, Otologic and Ocular Adverse Events -- Cancer Imaging in Immunotherapy -- The Microbiome in Immuno-Oncology -- New developments in the use of Patient-reported outcomes in Cancer Patients undergoing Immunotherapies.
Immunotherapy is a rapidly evolving field that mandates frequent revision of the book as new insights to fight cancer emerge. The third edition of Immunotherapy is an updated overview of immuno-oncology in different cancer types and toxicities associated with immunotherapy. It explores the breath of immunotherapeutic strategies available to treat a wide range of cancers, from melanoma and non-small cell lung cancer to gastrointestinal, genitourinary, gynecologic and nervous system malignancies. With increasing use of checkpoint inhibitors as standard of care and in clinical trials, the challenges associated with their use undoubtedly increase. As objective response is limited to a subset of patients and is often associated with distinct immune related side effects that are potentially life threatening, it is essential to identify patients who are likely to respond to immunotherapy and those who are at a risk for developing treatment-related side effects. In the absence of a validated predictive biomarker, innovative technologies and assays are being used to identify critical biomarkers that drive the immune response. Hence, a chapter to provide a basic understanding of the diagnostic procedures has been included besides the chapter on the cellular components of the human immune system. This new edition will also inform readers on use of novel microbiome and imaging approaches. Finally, the book includes a chapter on patient-reported outcomes in patients treated with immunotherapies as the authors recognize the importance of including missing patient voice in clinical trials and longitudinal assessment of symptom reports. In short, the third edition of this book provides a comprehensive overview of the latest developments in the field of immune-oncology that will help health care professionals make informed treatment decisions. The book’s chapters are written by a diverse cast of experts conducting cutting-edge research, providing the reader with the most up-to-date science.
ISBN: 9783030410087
Standard No.: 10.1007/978-3-030-41008-7doiSubjects--Topical Terms:
593951
Oncology.
LC Class. No.: RC261-271
Dewey Class. No.: 614.5999
Immunotherapy
LDR
:04367nam a22003975i 4500
001
1027725
003
DE-He213
005
20200702221251.0
007
cr nn 008mamaa
008
210318s2020 gw | s |||| 0|eng d
020
$a
9783030410087
$9
978-3-030-41008-7
024
7
$a
10.1007/978-3-030-41008-7
$2
doi
035
$a
978-3-030-41008-7
050
4
$a
RC261-271
072
7
$a
MJCL
$2
bicssc
072
7
$a
MED062000
$2
bisacsh
072
7
$a
MJCL
$2
thema
082
0 4
$a
614.5999
$2
23
245
1 0
$a
Immunotherapy
$h
[electronic resource] /
$c
edited by Aung Naing, Joud Hajjar.
250
$a
3rd ed. 2020.
264
1
$a
Cham :
$b
Springer International Publishing :
$b
Imprint: Springer,
$c
2020.
300
$a
XII, 339 p. 44 illus., 35 illus. in color.
$b
online resource.
336
$a
text
$b
txt
$2
rdacontent
337
$a
computer
$b
c
$2
rdamedia
338
$a
online resource
$b
cr
$2
rdacarrier
347
$a
text file
$b
PDF
$2
rda
490
1
$a
Advances in Experimental Medicine and Biology,
$x
0065-2598 ;
$v
1244
505
0
$a
Overview of Basic Immunology and Clinical Application -- Advances in Diagnostic Procedures and their Applications in the era of Cancer Immunotherapy -- Immunotherapy for Melanoma -- Immunotherapy in Lung Cancer: From a minor God to the Olympus -- Immunotherapy in Gastrointestinal Malignancies -- Current Landscape of Immunotherapy in Genitourinary Malignancies -- Immuno-oncology for Gynecologic Malignancies -- Immunotherapy for Neuro-Oncology -- Immunotherapy and Radiation -- CAR T-cells -- Skin Reactions to Immune Checkpoint Inhibitors -- Gastrointestinal Tract Adverse Events -- Immune-Related Adverse Events: Pneumonitis -- Hepatobiliary Adverse Events -- Immune Checkpoint Inhibitors (ICIs) Related Cardiotoxicity -- Renal Toxicity -- Immune-Related Oral, Otologic and Ocular Adverse Events -- Cancer Imaging in Immunotherapy -- The Microbiome in Immuno-Oncology -- New developments in the use of Patient-reported outcomes in Cancer Patients undergoing Immunotherapies.
520
$a
Immunotherapy is a rapidly evolving field that mandates frequent revision of the book as new insights to fight cancer emerge. The third edition of Immunotherapy is an updated overview of immuno-oncology in different cancer types and toxicities associated with immunotherapy. It explores the breath of immunotherapeutic strategies available to treat a wide range of cancers, from melanoma and non-small cell lung cancer to gastrointestinal, genitourinary, gynecologic and nervous system malignancies. With increasing use of checkpoint inhibitors as standard of care and in clinical trials, the challenges associated with their use undoubtedly increase. As objective response is limited to a subset of patients and is often associated with distinct immune related side effects that are potentially life threatening, it is essential to identify patients who are likely to respond to immunotherapy and those who are at a risk for developing treatment-related side effects. In the absence of a validated predictive biomarker, innovative technologies and assays are being used to identify critical biomarkers that drive the immune response. Hence, a chapter to provide a basic understanding of the diagnostic procedures has been included besides the chapter on the cellular components of the human immune system. This new edition will also inform readers on use of novel microbiome and imaging approaches. Finally, the book includes a chapter on patient-reported outcomes in patients treated with immunotherapies as the authors recognize the importance of including missing patient voice in clinical trials and longitudinal assessment of symptom reports. In short, the third edition of this book provides a comprehensive overview of the latest developments in the field of immune-oncology that will help health care professionals make informed treatment decisions. The book’s chapters are written by a diverse cast of experts conducting cutting-edge research, providing the reader with the most up-to-date science.
650
2 4
$a
Oncology.
$3
593951
650
1 4
$a
Cancer Research.
$3
668358
650
0
$a
Oncology .
$3
1253469
650
0
$a
Immunology.
$3
592892
650
0
$a
Cancer research.
$3
1253664
700
1
$a
Hajjar, Joud.
$4
edt
$4
http://id.loc.gov/vocabulary/relators/edt
$3
1139516
700
1
$a
Naing, Aung.
$4
edt
$4
http://id.loc.gov/vocabulary/relators/edt
$3
1139515
710
2
$a
SpringerLink (Online service)
$3
593884
773
0
$t
Springer Nature eBook
776
0 8
$i
Printed edition:
$z
9783030410070
776
0 8
$i
Printed edition:
$z
9783030410094
830
0
$a
Advances in Experimental Medicine and Biology,
$x
0065-2598 ;
$v
889
$3
1253792
856
4 0
$u
https://doi.org/10.1007/978-3-030-41008-7
912
$a
ZDB-2-SBL
912
$a
ZDB-2-SXB
950
$a
Biomedical and Life Sciences (SpringerNature-11642)
950
$a
Biomedical and Life Sciences (R0) (SpringerNature-43708)
筆 0 讀者評論
多媒體
評論
新增評論
分享你的心得
Export
取書館別
處理中
...
變更密碼[密碼必須為2種組合(英文和數字)及長度為10碼以上]
登入